# Benitec Biopharma Inc.: overview BNTC · Nasdaq · CIK 1808898 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jun 30 Pages: [Overview](/companies/bntc.md) · [Financials](/companies/bntc/financials.md) · [Filings](/companies/bntc/filings.md) · [Insiders](/companies/bntc/insiders.md) Latest reported revenue: [$0](/filings/0001193125-26-222885.md) for Q3 FY2026, three months to 2026-03-31, from the 10-Q filed May 14, 2026 (XBRL us-gaap:Revenues, accession 0001193125-26-222885). ## Last eight quarters | Line item | Unit | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [0.0](/filings/0001193125-25-283274.md) | [0.0](/filings/0001193125-26-047737.md) | [0.0](/filings/0001193125-26-222885.md) | not reported | [0.0](/filings/0001193125-25-283274.md) | [0.0](/filings/0001193125-26-047737.md) | [0.0](/filings/0001193125-26-222885.md) | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.18)](/filings/0001193125-26-117604.md) | [(0.26)](/filings/0001193125-26-047737.md) | [(0.38)](/filings/0001193125-26-222885.md) | [(0.21)](/filings/0001193125-26-117604.md) | [(0.22)](/filings/0001193125-25-283274.md) | [(0.26)](/filings/0001193125-26-047737.md) | [(0.24)](/filings/0001193125-26-222885.md) | not reported | | Free cash flow | $k | not reported | not reported | [(3,092) d](/filings/0001193125-26-222885.md) | [(8,213) d](/filings/0001193125-26-390570.md) | not reported | not reported | [(4,467) d](/filings/0001193125-26-222885.md) | [(5,018) d](/filings/0001193125-26-390570.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. ## Last five fiscal years | Line item | Unit | FY2022 (2022-06-30) | FY2023 (2023-06-30) | FY2024 (2024-06-30) | FY2025 (2025-06-30) | FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.1](/filings/0001193125-23-239121.md) | [0.1](/filings/0001193125-24-226968.md) | [0.0](/filings/0001193125-24-226968.md) | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(24457.5%)](/filings/0001193125-23-239121.md) | [(25441.3%)](/filings/0001193125-24-226968.md) | not reported | not reported | not reported | | Net margin | % | [(24942.5%)](/filings/0001193125-23-239121.md) | [(26082.7%)](/filings/0001193125-24-226968.md) | not reported | not reported | not reported | | Diluted EPS | $ per share | [(37.88)](/filings/0001193125-23-239121.md) | [(14.12)](/filings/0001193125-24-226968.md) | [(1.22)](/filings/0001193125-26-117604.md) | [(1.05)](/filings/0001193125-26-390570.md) | [(0.98)](/filings/0001193125-26-390570.md) | | Free cash flow | $m | [(15.9)](/filings/0001193125-23-239121.md) | [(18.0)](/filings/0001193125-24-226968.md) | [(19.6)](/filings/0001193125-26-117604.md) | [(23.6)](/filings/0001193125-26-390570.md) | [(16.6)](/filings/0001193125-26-390570.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/bntc/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [MONTANOVA CAPITAL, LLC](/funds/1569064.md) | 2026-06-30 | $154.5m | 11,548,351 | | Unchanged | | [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $33.1m | 2,478,547 | | Not compared | | [FRANKLIN RESOURCES INC](/funds/38777.md) | 2026-06-30 | $32.3m | 2,412,888 | | Added +34,729 | | [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $30.7m | 2,876,380 | | Not compared | | [ADAGE CAPITAL PARTNERS GP, L.L.C.](/funds/1165408.md) | 2026-06-30 | $28.4m | 2,120,672 | | Unchanged | | [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $24.8m | 1,850,000 | | Unchanged | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $19.9m | 1,488,371 | | Added +50,000 | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $19.9m | 1,488,371 | | Added +50,000 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $18.8m | 1,407,138 | | Added +221,397 | | [Simplify Asset Management Inc.](/funds/1846368.md) | 2026-06-30 | $13.5m | 1,005,557 | | Added +443,315 | ## Recent filings [All 323 filings](/companies/bntc/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-20 | 16:25 ET | [DEF 14A](/filings/0001193125-26-426733.md) | Proxy statement, period 2026-10-20 | 0001193125-26-426733 | | 2026-10-05 | 08:08 ET | [8-K](/filings/0001193125-26-413177.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-413177 | | 2026-09-30 | 16:08 ET | [8-K](/filings/0001193125-26-409052.md) | 4.01 Change of auditor | 0001193125-26-409052 | | 2026-09-24 | 16:38 ET | [8-K](/filings/0001193125-26-401110.md) | 4.01 Change of auditor; 9.01 Financial statements and exhibits | 0001193125-26-401110 | | 2026-09-14 | 16:09 ET | [10-K](/filings/0001193125-26-390570.md) | Annual report, period 2026-06-30 | 0001193125-26-390570 | | 2026-09-14 | 16:04 ET | [8-K](/filings/0001193125-26-390539.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-390539 | | 2026-05-29 | 16:10 ET | [8-K](/filings/0001193125-26-248289.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-248289 | | 2026-05-14 | 08:10 ET | [10-Q](/filings/0001193125-26-222885.md) | Quarterly report, period 2026-03-31 | 0001193125-26-222885 | | 2026-05-14 | 08:09 ET | [8-K](/filings/0001193125-26-222879.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-222879 | | 2026-03-20 | 16:03 ET | [10-K/A](/filings/0001193125-26-117604.md) | Annual report, amended, period 2025-06-30 | 0001193125-26-117604 | ## Latest annual report [Form 10-K for the fiscal year ended Jun 30, 2026](/filings/0001193125-26-390570.md), filed Sep 14, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1808898 - Tickers: BNTC - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 28, 2026, 08:04 ET. No prices; not investment advice.